Several new post-hoc analyses from the TONADO 1&2 and OTEMTO 1&2 studies were presented at CHEST 2015 and, according to Boehringer Ingelheim Pharmaceuticals, the studies showed positive data for COPD patients using Stiolto Respimat.

One analysis showed significant lung function improvement, as measured by FEV1 AUC0–3, with once daily Stiolto Respimat across a range of age groups of COPD patients (adult patients less than 65 years, 65-75 years, 75-85 years, and 85+ years).

In addition, there were two analyses which showed treatment reduced the frequency of night-time rescue medication use, as measured by puffs needed per night, and improved the score of Transition Dyspnea Index (TDI) in COPD patients, compared to tiotropium, olodaterol, or placebo.

Stiolto Respimat was approved in May 2015 for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. Stiolto Respimat is not indicated to treat asthma or acute deterioration of COPD.

Long-acting beta2-adrenergic agonists, such as olodaterol, one of the active ingredients in Stiolto Respimat, increase the risk of asthma-related death. Stiolto Respimat is not indicated for asthma and should not be initiated in acutely deteriorating COPD patients or for the relief of acute symptoms. Stiolto Respimat is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product. As with other inhaled medicines, Stiolto Respimat may cause paradoxical bronchospasm, which means breathing or wheezing worsen, that may be life-threatening. The most common adverse reactions were nasopharyngitis (common cold), cough and back pain.

“As a leader in COPD care for more than 40 years in the US, we’re encouraged by these data as we continue to explore the potential benefits of Stiolto Respimat for COPD patients,” said Danny McBryan, MD, vice president, Clinical Development & Medical Affairs, Respiratory, Boehringer Ingelheim.